SCHEMBL6930593

SCHEMBL6930593

N#Cc1cccc(C(=O)Nc2ccc(C(=O)CCC(=O)O)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.53
POLB P06746 2/20 0.53
KMT2A Q03164 2/20 0.53
PLAU P00749 2/20 0.51
F2 P00734 1/20 0.51
PLG P00747 1/20 0.51
KLKB1 P03952 1/20 0.51
PRSS1 P07477 1/20 0.51
NAMPT P43490 1/20 0.50
MEN1 O00255 1/20 0.50
GRM5 P41594 3/20 0.49
CCR2 P41597 1/20 0.49
GSK3B P49841 1/20 0.48
SLC2A1 P11166 1/20 0.48
SIRT2 Q8IXJ6 1/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
BRAF P15056 1/20 0.47
P2RY2 P41231 1/20 0.47
GPR17 Q13304 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6932764 0.86 PLAU (0.47) KMT2APLAUF2PLGKLKB1
SCHEMBL6932768 0.86 PLAU (0.47) KMT2APLAUF2PLGKLKB1
SCHEMBL6926015 0.85 MAPT (0.58) MAPTPOLBKMT2APLAUF2
SCHEMBL31542041 0.84 GSK3B (0.66) KMT2AGSK3BLMNASMN1; SMN2
SCHEMBL31219284 0.82 HTT (0.62) MAPTKMT2APLAUF2PLG
SCHEMBL9587298 0.82 MEN1 (0.65) MAPTPOLBKMT2APLAUF2
SCHEMBL6927758 0.81 NR4A2 (0.67) MAPTPOLBKMT2AMEN1LMNA
SCHEMBL6925556 0.81 NPC1 (0.64) MAPTKMT2AMEN1LMNASMN1; SMN2
SCHEMBL6931919 0.80 KMT2A (0.70) POLBKMT2AMEN1SMN1; SMN2
SCHEMBL22531833 0.79 TP53 (0.71) MAPTKMT2APLAUF2PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624196-B2 Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders WARNER-LAMBERT COMPANY 2003-09-23 US claimed
US-6541521-B1 Particularly gelatinase A, collagenase-3, and stromelysin-1 WARNER-LAMBERT COMPANY 2003-04-01 US claimed
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 2002-10-31 US claimed
US-6624196-B2 Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders WARNER-LAMBERT COMPANY 2003-09-23 US disclosed
US-6541521-B1 Particularly gelatinase A, collagenase-3, and stromelysin-1 WARNER-LAMBERT COMPANY 2003-04-01 US disclosed
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 2002-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases MMP1, MMP8, MMP13 MAPT 718/4885POLB 237/4885KMT2A 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.